About: Polymers in the Delivery of siRNA for the Treatment of Virus Infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Polymers in the Delivery of siRNA for the Treatment of Virus Infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Polymers in the Delivery of siRNA for the Treatment of Virus Infections
Creator	Dearnley, Megan Hinton, Tracey Reynolds, Nicholas Au, Hinton, M Hinton@csiro, Tracey Tracey, •
topic	covid:f209f24f242bc7a5b511229431304ba917ad418f#this
Source	PMC
abstract	Viral diseases remain a major cause of death worldwide. Despite advances in vaccine and antiviral drug technology, each year over three million people die from a range of viral infections. Predominant viruses include human immunodeficiency virus, hepatitis viruses, and gastrointestinal and respiratory viruses. Now more than ever, robust, easily mobilised and cost-effective antiviral strategies are needed to combat both known and emerging disease threats. RNA interference and small interfering (si)RNAs were initially hailed as a ‘‘magic bullet’’, due to their ability to inhibit the synthesis of any protein via the degradation of its complementary messenger RNA sequence. Of particular interest was the potential for attenuating viral mRNAs contributing to the pathogenesis of disease that were not able to be targeted by vaccines or antiviral drugs. However, it was soon discovered that delivery of active siRNA molecules to the infection site in vivo was considerably more difficult than anticipated, due to a number of physiological barriers in the body. This spurred a new wave of investigation into nucleic acid delivery vehicles which could facilitate safe, targeted and effective administration of the siRNA as therapy. Amongst these, cationic polymer delivery vehicles have emerged as a promising candidate as they are low-cost and easy to produce at an industrial scale, and bind to the siRNA by nonspecific electrostatic interactions. These nanoparticles (NPs) can be functionally designed to target the infection site, improve uptake in infected cells, release the siRNA inside the endosome and facilitate delivery into the cell cytoplasm. They may also have the added benefit of acting as adjuvants. This chapter provides a background around problems associated with the translation of siRNA as antiviral treatments, reviews the progress made in nucleic acid therapeutics and discusses current methods and progress in overcoming these challenges. It also addresses the importance of combining physicochemical characterisation of the NPs with in vitro and in vivo data.
has issue date	2017-03-21(xsd:dateTime)
bibo:doi	10.1007/978-3-319-77866-2_11
has license	no-cc
sha1sum (hex)	f209f24f242bc7a5b511229431304ba917ad418f
schema:url	https://doi.org/10.1007/978-3-319-77866-2_11
resource representing a document's title	Polymers in the Delivery of siRNA for the Treatment of Virus Infections
has PubMed Central identifier	PMC7123685
schema:publication	Polymeric Gene Delivery Systems
resource representing a document's body	covid:f209f24f242bc7a5b511229431304ba917ad418f#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/f209f24f242bc7a5b511229431304ba917ad418f
is schema:about of	named entity 'POTENTIAL' named entity 'INTERFERING' named entity 'DISEASE' named entity 'MILLION' named entity 'SOON' named entity 'COMBAT' named entity 'ADMINISTRATION' named entity 'THEIR' named entity 'INCLUDE' named entity 'NEEDED' named entity 'ANTIVIRAL' named entity 'VIRAL INFECTIONS' named entity 'TARGET' named entity 'SIRNA' named entity 'electrostatic interactions' named entity 'Viral diseases' named entity 'emerging disease' named entity 'RNAs' named entity 'cost-effective' named entity 'siRNA' named entity 'hepatitis viruses' named entity 'stiffness' named entity 'siRNA' named entity 'permeability' named entity 'varicella-zoster virus' named entity 'lipid' named entity 'DLS' named entity 'siRNA' named entity 'polymer' named entity 'cytomegalovirus retinitis' named entity 'gene silencing' named entity 'cell cytoplasm' named entity 'exogenous' named entity 'viral vectors' named entity 'immune response' named entity 'modern medicine' named entity 'RNAs' named entity 'hybridisation' named entity 'epidemics' named entity 'Environmental scanning electron microscopy' named entity 'RISC' named entity 'chorioallantoic membrane' named entity 'vacuum' named entity 'particle sizing' named entity 'epithelial cells' named entity 'polymer' named entity 'particle size' named entity 'SEM' named entity 'positive charge' named entity 'Viral vectors' named entity 'recombinant' named entity 'progenitor cells' named entity 'morbidity' named entity 'stages of development' named entity 'chemotherapy' named entity 'DLS' named entity 'siRNAs' named entity 'naturally occurring' named entity 'plasmids' named entity 'HLA-DR' named entity 'scattering' named entity 'DGCR8' named entity 'vaccination' named entity 'siRNA' named entity 'genetic material' named entity 'adverse effects' named entity 'renal filtration' named entity 'cardiovascular disease' named entity 'mRNA transcript' named entity 'influenza' named entity 'double-stranded' named entity 'siRNA' named entity 'cell membrane' named entity 'IL1b' named entity 'siRNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software